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Type 1 Diabetes (T1D) results from insulin-producing beta cells destruction by diabetogenic T lymphocytes in humans and
nonobese diabetic (NOD) mice. The breakdown of tolerance has been associated with a defect in the number and the function of
naturally occurring regulatory T cells (nTreg) that are the master player in peripheral tolerance. Gene knockout experiments in
mouse models have shown a nonredundant activity of IL-2 related to its critical role in inducing nTreg and controlling peripheral
T cell tolerance. Whereas strong evidence has suggested that IL-2 is critically required for nTreg-mediated T1D control, several
fundamental questions remain to be addressed. In this paper, we highlight the recent ﬁndings and controversies regarding the
tolerogenic properties of IL-2 mediated through nTreg. We further discuss a potential link between the immunomodulatory role
of interleukin-2 and the pathogenesis of type 1 diabetes.
1.Introduction
The induction of tolerance is critical for the maintenance
of immune homeostasis and the prevention of autoimmune
diseases, including type 1 diabetes (T1D). Tregs are crucial
for suppressing autoimmune responses and maintaining
peripheral immunological tolerance [1]. Defects in the
number and function of immunoregulatory CD4+ T cells
(nTregs) play a critical role in the breakdown of immune
tolerancein the experimental model ofspontaneous autoim-
mune diabetes nonobese diabetic (NOD) mouse [2, 3]a n d
in humans with genetic susceptibility to T1D. Tregs arise
during the normal process of T cell maturation in the
thymus, and their diﬀerentiation can be induced ( iTreg) in
the periphery by conversion of naive CD4+CD25−Foxp3−
Tregs into CD4+CD25+Foxp3+ Tregs [4, 5]. The inﬂuence of
nTregs in maintaining T cell tolerance is strongly supported
by the observations of the development of autoimmune
syndromes in mice lacking nTregs and by the ﬁndings
that defects in Foxp3 gene expression in humans and mice
lead to autoimmune syndromes in early life [6, 7]. In
agreement with these observations, the prevention of other
autoimmune diseases such as rheumatoid arthritis (RA),
inﬂammatory bowel disease (IBD), and type 1 diabetes
(T1D) has been achieved by reconstitution of autoimmune-
p r o n em i c ew i t hn T r e g s[ 8]. Emerging evidence has revealed
the involvement of IL-2 as a major regulator of the survival
and suppressive function of nTreg [9, 10]. Work from
Santamaria’s group [11] has revealed that IL-2 production
wasreducedinNODmiceandcorrelatedwithimpairmentin
nTreg function. Furthermore, treatment with IL-2 has been
shown to induce Treg expansion and activation in humans
and mice [9] and protection against diabetes in NOD mice
[12]. In the last decade, much progress has been made in2 Clinical and Developmental Immunology
understanding the role of the IL-2/IL-2 receptor (IL-2R)
axis in promoting nTreg diﬀerentiation and its importance
in the interface between tolerance and autoimmunity. This
paper primarily focuses on our current understanding of the
role of IL-2/nTreg in regulating autoimmune diabetes and
its potential therapeutic application in patients with T1D.
Recently, it has been shown that the administration of low
doses of IL-2 at the onset of diabetes can induce a long-
lasting remission in NOD mice. Interestingly, IL-2 did not
stimulate autoreactive eﬀector T cells but rather speciﬁcally
stimulated CD4+Foxp3+ Tregs in the pancreas, resulting in
dampening the inﬂuence of the inﬂammatory environment
[12]. Here, we further highlight the role of IL-2/IL-2R in
autoimmune T1D, speciﬁcally through the modulation of
nTregs developmentand function.
2.Biological Importanceof
IL-2/IL-2RSignaling
IL-2isa15kDa4-bundledα-helicalproteinmainlyproduced
by activated CD4+ T lymphocytes. However, the expression
of IL-2 by na¨ ıve CD8+ T cells, dendritic cells, and thymic
cells has also been reported [13, 14]. The magnitude and
duration of the T cell immune response is dependent on
the interaction of IL-2 with its high-aﬃnity IL-2 receptor
(IL-2R) which is composed of α, β and γ subunits. The
intermediate aﬃnity IL-2R is composed of IL-2Rβ (CD122)
and IL-2Rγ (CD132) and is constitutively expressed on
resting T lymphocytes. However, IL-2Rα (CD25) is only
induced after T-cell activation, which allows the formation
of the high-aﬃnity IL-2R [15]. The biological activities
resulting from the binding of IL-2 to its receptor on T-
cells have not yet been fully deﬁned. Evidence has shown
that in conventional T cells, the eﬀects of occupation of
the high aﬃnity IL-2R are mediated by at least two major
signaling pathways, the JAK-STAT and the PI3K pathways.
The activation of the JAK-STAT pathway is initiated by the
activation of the Janus Kinases (JAK) JAK1 and JAK3. JAK1
is primarily associated with the serine-rich region of the
IL-2R, whereas JAK3 seems to be associated with both the
proximal and distal regions of the cytoplasmic domain of the
common γ-chain. The stimulation of JAKmolecules initiates
a cascade of activation involving the signal transducers and
activators of transcription (STAT5a/b) factors as well as
the phosphatidylinositol 3-kinse (PI3K) and ras-mitogen-
activated protein kinase (MAPK) signaling pathways [15,
16]. The activation of these signaling molecules results in
modulation of target gene expression involved in cell cycle
progression (gene encoding cycling family proteins A, B, C,
D2, D3, and E), anti-apoptosis (Cmyc, C-fos, C-jun, Bcl2,
and bclx), and in the suppression of cytokine (SOCS and
CIS) signaling (Figure 1)[ 17, 18].
The JAK/STAT5 pathway is important for many cellular
responses, includingdiﬀerentiation, proliferation, and onco-
genesis. For example, STAT5−/−mice have a profound defect
in mammary gland development and in prolactin response,
whereasSTAT5B−/− micedisplayadefectingrowthhormone
response [19].Simultaneousinactivation ofSTAT5A/Bgenes
has revealed a requirement for both proteins in myeloid
and lymphoid cell proliferation. Indeed, myeloid cells, mast
cells, peripheral T cells, and NK and B cells display impaired
proliferation and/or survival in STAT5−/− mice [20–22].
STAT5 has also been shown to be involved in maintaining
CD4+CD25+ regulatoryTcellhomeostasisandself-tolerance
[23], Th2 diﬀerentiation, and CD8+ T cell homeostasis
[24]. STAT5−/− mice have a decreased number of CD8+
T cells, whereas STAT5 transgenic mice have an increased
number of these cells, which correlates with anti-apoptotic
protein Bcl-xL expression [25]. Ectopic expression of Bcl-
x rescues STAT5−/− BM cells from apoptosis indicating
that STAT5 promotes survival of myeloid progenitor cells
through the ability to induce the transcription of the Bcl-
xg e n e[ 26]. Finally, STAT5−/− mice exhibit autoimmune
pathology in a manner very similar to IL-2-deﬁcient mice.
This disease correlates with decreased numbers of nTregs,
which undergo apoptosis at increased rates in the absence
of STAT5 [26]. Recently, it has been reported that a patient,
with a missense mutation in the STAT5B gene, had no
detectableexpressionofSTAT5Band had decreasednumbers
and impaired function of nTregs [27]. Similarly, JAK3−/−
mice have low frequency of nTregs, increased amount of
autoreactive T cells, and develop autoimmunity as is the
case for IL-2-deﬁcient and IL-2R-deﬁcient mice [23]. These
reports underlie the importance of IL-2/IL-2R signaling in
the maintenance of immune tolerance.
3.NaturallyOccurringCD4+CD25+
Tregsand Autoimmunity
NaturallyoccurringCD4+CD25+ regulatory Tcellsrepresent
5%–10% of the CD4+ T cell subset that critically contributes
to maintenance of peripheral immune tolerance. These cells
arise in the thymus and, after migrating to the periphery,
exert their immunoregulatory functions. They are potent
suppressor of organ-speciﬁc autoimmune diseases such as
T1D, inﬂammatory bowel disease and gastritis, and they
control allograft rejection and immunity to infectious agents
suchasparasitesandviruses[28–30].Inmice,aday-3neona-
tal thymectomy (d3Tx) leads to the developmentof multior-
gan autoimmunedisease [31].Subsequently,the depletionof
CD4+CD25+ Tregsleadstospontaneousdevelopmentofvar-
ious autoimmune diseases in genetically susceptible animals
as well. The adoptive transfer of CD4+CD25+ nTreg prevents
the development of such organ-speciﬁc autoimmunity [32].
In the T1D NOD mouse model, it has been shown that
the pool of CD4+CD25+ regulatory T cells decreases with
the progression of diabetes [33, 34] and that administration
of these cells aﬀords protection against the development of
diabetes [35, 36] .I nt h em o u s e ,n T r e ga r ec o n s i d e r e da s
resting antigen-experienced cells and display heterogeneous
combination of cell surface markers associated with naive
and activated T cells. nTregs constitutively express high-
aﬃnity IL-2Rα (CD25) and Foxp3, a forkhead winged helix
transcriptional regulatorthatcontrolstheirdevelopmentand
functions [37]. The mutation of Foxp3 resulted in drastic
lossofnTregsandfatallymphoproliferativeprocessthatleads
to multiorgan-autoimmune diseases of nTregs in mice and
humans. The transfer of nTreg cells from wild-type miceClinical and Developmental Immunology 3
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Figure 1:IL-2 receptor signaling.The binding ofIL-2 to IL-2R leads to the initiation of signal transduction.Janus-activated kinase3 (JAK3)
molecules that are associated with the γc, and JAK1 molecules that are associated with IL-2Rβ, phosphorylate (the red circle) tyrosine
residues in the cytoplasmic tail of IL-2Rβ,t h eγc and the JAK molecules themselves. The JAKs activation induced a cascade of activation
of signal transducer and activator of transcription (STAT5a/b) factors, leading to their dimerization translocation to the nucleus, as well
as phosphatidylinositol 3-kinse (PI3K) and ras-mitogen-activated protein kinase (MAPK) signaling pathways. These signaling molecules
activation results in, modulation of target genes expression involved in cell cycles progression, antiapoptosis, and in the suppression of
cytokine signaling.
to scurfy mice rescues the animals from the fatal disease
[7, 38]. Other cell surface markers have been shown to be
expressed by nTregs, including high levels of CD5, CD62L,
and CD69. Beside the expression of high-aﬃnity IL-2Rα
(CD25), at resting state, nTreg constitutively express high
levels of other feature markers such as the glucocorticoid-
induced TNFR (GITR) family of related proteins [39],
OX40 (CD134) [40, 41], and CTLA-4 [42, 43]t h a ta l s o
contribute to their suppressive function. Importantly, mice
deﬁcient in Foxp3 gene (scurfy mice) rapidly develop a
fatal lymphoproliferative disease similar to that seen in mice
lacking CTLA-4 or TGF-β [44]. Recently, it has been shown
that OX40 is a key factor in shaping nTregs sensitivty to
IL-2 and promoting their proliferation and survival toward
accurate immune regulation [45].
We have previously reported that tolerogenic DCs are
critical in maintaining nTregs pool in NOD mice. Using
adoptivetransfer experiments, we have shown that depletion
of tolerogenic DCs before transferring splenocytes from
diabetes-free NOD mice restored their diabetogenic poten-
tial, thereby underlying the importance of tolerogenic DC
in nTregs maintenance [46]. Na¨ ıve CD4+CD25− T cells
can be also converted into regulatory-like T cells after
transduction with a retroviral vector coding for the FoxP3
gene. The transfer of these converted Tregs has been shown
to prevent the development of autoimmune IBD [5, 38, 47].
Collectively, these data clearly indicate that Foxp3 plays a
critical role for both development and function of nTreg in
mice.4 Clinical and Developmental Immunology
4.CytokinesProﬁleandCytokines
ReceptorSignaling innTreg
The mechanisms by which IL-2 or other cytokinesexert their
eﬀectsviathecytokinereceptorsonnTreghavenotbeenfully
investigated yet. In conventional T cells, the eﬀects of IL-2
are mediated by at least two major signaling pathways, the
JAK-STAT and PI3K pathways. Several diﬀerent studies have
examined the role of JAK-STAT molecules in CD4+CD25+
nTreg development and function. The importance of JAK3
in IL-2 signaling has been further substantiated by the recent
ﬁndings that homozygous point mutations or deletions
of the Jak3 gene are found in autosomal recessive T-B+
severe combined immunodeﬁciency patients [48]a sw e l l
as immunocompromised mice [49]. Indeed, mice deﬁcient
in JAK3 or STAT5A/B develop a severe immunodeﬁciency
that is followed by multiple organ autoimmune diseases, a
decreased number or the absence of CD4+CD25+ nTreg in
their peripheral lymphoid organs, and early death. However,
t h e s em i c eh a v en o r m a ln u m b e r so fT r e g si nt h et h y m u s ,
suggesting the role of these molecules in regulatory T cell
development and homeostasis [23, 26]. Interestingly, the
overexpression of STAT5b in transgenic mice leads to an
increased number of CD4+CD25+ nTreg [50].
The role of JAK-STAT and PI3K signaling pathways in
Treg proliferation and immunoregulatory function is not yet
fully deﬁned. Recently, Bensinger et al. [51]h a v es h o w nt h a t
freshly isolated CD4+CD25+ nTreg maintain an intact JAK-
STATsignalingpathway,whereas signalingdownstreamPI3K
(particularly activation of AKT and p70S6K) is negatively
regulated as a result of increased expression of phosphatase
and a tensin homolog deleted on chromosome 10 (PTEN).
Conversely,wefoundthatin vitro stimulatedTregdisplayeda
normal PI3K pathway while inhibiting JAK-STAT pathways,
which resultsfromadownregulationofJAK-STATmolecules
expression as opposed to kinase activity (Chentouﬁ et
al. Unpublished data). The inhibition of the JAK-STAT
pathway could result from the high expression of SOCS-
2 and CIS molecules observed 24–48h following nTreg
stimulation with anti-CD3 and IL-2. These results may
explain the hypoproliferative activity of regulatory T cells
even after activation through TCR in the presence of IL-
2. Moreover, IL-2 generates signaling pathways through a
cytokine receptor that contains a γ-chain common to several
other cytokine receptors including IL-4, IL-7, IL-9, IL-15,
and IL-21. These observations add more complexity to
the problem of deciphering the role of other cytokines on
CD4+CD25+ nTreg.
Recently, it has been reported that IL-4 can substitute
forIL-2toinduceCD4+CD25+ nTreg-mediated proliferation
and suppression in vitro. However, nTreg obtained from IL-
4−/− mice display normal suppressive activity, suggesting
profounddiﬀerencesbetweenin vitro andin vivoeﬀects[52].
It has also been shown that STAT1-deﬁcient mice are highly
susceptible to autoimmune diseases resulting from a reduced
number as well as a functional impairment of CD4+CD25+
nTreg, suggesting a role of IFNs on regulatory T cells
[53]. Naturally occurring CD4+CD25+ T cells constitutively
express mRNA coding for IL-10, IL-4, IL-17, IL-21, IFN-γ,
TNF-α,a n dT G F - β but do not express mRNA coding for IL-
2[ 43].
The biological roles of cytokinesproduction and interac-
tion with their receptors in nTreg development and function
have not yet been clearly delineated. Recently, McHugh
et al. [43] have shown, through gene expression proﬁling
experiments, that JAK-STAT regulatory proteins such as
members of the SOCS family of proteins (SOCS-1, SOCS-3,
andCIS)areupregulatedinstimulatedCD4+CD25+ nTregas
compared to conventionalT cells [43]. The hypoproliferative
activity of activated nTreg in vitro and the increased expres-
sion of SOCS molecules could suggest that these molecules
playaroleasaninternalcontrolmechanism forCD4+CD25+
nTreg activation and expansion. SOCS molecules function to
inhibit the proliferative eﬀects of cytokines such as IFN-γ,
IL-4, and IL-2 and can antagonize JAK3 and STAT5 activities
[18].
5.CriticalBalance ofIL-2 for
NaturallyOccurringCD4+CD25+
Treg-Mediated T1D Control
IL-2 was originally deﬁned as a growth factor that stimulated
the diﬀerentiation and proliferation of T lymphocytes [54].
The critical role of IL-2 on the survival and suppressive
function of nTreg cells has been well documented [55].
Consistent with this, IL-2 administration has been shown to
expand and activate nTreg cells in humans and mice [9, 10].
Thus, although IL-2 has pleiotropic functions, its majorClinical and Developmental Immunology 5
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Figure 2: Fundamental questions about naturally occurring CD4+ CD25+ regulatory T cells development and function.
impact is to favor nTreg cell activity [56]. Surprisingly, in IL-
2 or IL-2R knockout mice, T cells develop, and these mice
acquire a lymphoproliferative syndrome and spontaneous
autoimmunedisease [57].Fromthesestudies,twoimportant
roles for IL-2 in immune tolerance can be ascribed. First, the
data showed that IL-2 played a critical role in programming
T cells for activation-induced cell death (AICD). Second,
increased evidence showed that IL-2 played an additional
role in immune regulation aside from AICD. For instance,
severalgroupshavereportedthatinIL-2andIL-2Rknockout
mice, the lymphoproliferative syndrome could be prevented
by rIL-2 injection and bone marrow transplantation from
w i l d - t y p em i c e[ 58].
Of importance, it was observed that IL-2 had to be
provided at very early stages. For instance, delivery of IL-
2 a few days after birth resulted in low eﬃciency of disease
i m p r o v e m e n t ,s u g g e s t i n gt h a ti tw a sn o tt h el a c ko fI L - 2
duringlaterTcellactivation intheperipherythatwasatfault
inthesemice. The dependenceofnTreg cellsonIL-2 was ﬁrst
suggested by transfer experiments performed by Klebb et al.
Theseauthorstransferred spleencellsorthymocytesfromIL-
2−/− mice treated with rIL-2 for 25–35 days into untreated
6–8-day-old IL-2−/− BALB/C mice. The IL-2 defect on the
BALB/C background is particularly severe and leads to death
within 3 weeks. Depending on the number of transferred
cells and the organ from which they were derived, some of
the recipients lived for 7–10 months. Since no more IL-2 was
available during that time, the authors suggested that “IL-2
induces a postnatal diﬀerentiation/maturation of regulatory
cells necessary for self and non-self-discrimination”. Kramer
et al. have shown that IL-2−/− and IL-2R−/− bone marrow
transfer into RAG−/− mice leads to the developmentof IL-2
deﬁciency syndrome, and early death of RAG−/− recipient
mice [59].
Again, the disease could be prevented by the comple-
mentation with bone marrow from IL-2-suﬃcient mice.
Transfer of CD4+CD25+ nTreg from wild-type mice induced
the development of a lymphoproliferative syndrome in IL-
2Rα−/− mice [60]. The most striking observation in IL-
2−/− mice models is the lack of CD4+ CD25+ nTreg,
suggesting a critical role for IL-2/IL-2R signaling in the
generation and homeostasis of these cells. Indeed, mice
deﬁcient in IL-2, IL-2R [61], JAK-3 [23], or STAT5A/B
[26] have an absent or reduced number of thymic and
peripheral CD4+ CD25+ nTreg and consequently develop
multiple organ autoimmune diseases. To evaluate the role of
IL-2 expression on thymic nTreg development, Malek et al.
rescuedIL-2RβknockoutmicewithanIL-2Rβtransgenethat
was predominantly expressed in the thymus with negligible
expression in the periphery [60, 61]. In marked contrast to
IL-2Rβ−/− mice, the IL-2Rβ transgene restored the normal
levelsofCD4+CD25+ nTregandpreventedtheonset ofafatal
autoimmunedisease, further reinforcing thenotion that IL-2
plays a critical role in the thymic development of nTreg.
The molecular mechanism by which IL-2 exerts its eﬀect
o nt h en T r e gc e l lp r e c u r s o r si nt h et h y m u si sa so fy e t
not completely understood. In addition, the origin of IL-
2 in the thymus does not seem to be from CD4+CD25+
nTregthemselvesorhematopoieticcells,butprobablyderives6 Clinical and Developmental Immunology
from radio-resistant thymic stromal cells. Indeed, chimeric
bone marrow from IL-2−/− and IL-2Rα−/− mice develops
functional CD4+CD25+ nTreg. Furthermore, lethally irra-
diated RAG2−/− mice that have been reconstituted with
IL-2−/− bone morrow develop normal CD4+CD25+ nTreg
[62]. The IL- 2 signaling requirement for peripheral expan-
sion/homeostasis of CD4+CD25+ nTreg has been shown by
Malek et al. when CD4+CD25+ nTreg from wild-type mice
were adoptively transferred to IL-2R deﬁcient mice (which
normally produce IL-2). The recipient mice did not develop
autoimmune diseases. In contrast, the adoptive transfer of
CD4+CD25+ nTreg from wild-type mice failed to confer the
same beneﬁts in IL-2−/− mice [61].
The requirement of IL-2 for nTreg suppression activ-
ity is still very controversial. When nTreg are adoptively
transferred, they lose CD25 expression and hence are no
longer responsive to IL-2. Nevertheless, these cells retain
their suppressive activity in vitro [63]. However, the addition
of IL-2 to nTreg eliminates this suppressive activity in
vitro [64]. Conversely, CD4+CD25+ nTreg from wild-type
mice transferred to IL-2-deﬁcient mice fail to prevent
autoimmunity and in vitro suppression activity is completely
abrogated by selective blocking of the IL-2 receptor on
nTreg during a coculture with responder T cells [65].
Furthermore, treatment of mice with anti-IL-2 or with
CTLA-4 immunoglobulin to inhibit costimulatory signals
also leads to a rapid decline in the number of CD4+CD25+
T cells [36].
Besides, NOD mice present a qualitative diminution of
IL-2 production [11], and a genetic predisposing factor to
T1D development in humans and NOD mice is linked to
IL-2/IL-2R gene polymorphisms [66]. It has been recently
reported that insuﬃcient IL-2 amounts in the pancreas are
responsible for poor nTreg cell survival in this tissue, which
could lead to progressive breakdown of self-tolerance and
the development of diabetes in NOD mice [67]. It has been
recently shown that young prediabetic NOD mice treated
with low-dose IL-2 alone, or together with rapamycin, can
be protected from the development of disease [67–69].
Recently, it has been shown that low-dose IL-2 adminis-
tration at diabetes onset can induce long-lasting remission
in the treated mice. Interestingly, IL-2 seems to speciﬁcally
stimulate the CD4+CD25+ Treg cells in the pancreas rather
diabetogenic eﬀector T cells [12]. The mechanisms by which
IL-2 selectively stimulate Tregs and reverse the disease in
NOD diabetic mice is not yet understood. One mechanism
of action of low-dose IL-2 would be the limitation of IFN-
γ production by the islet-inﬁltrating eﬀector T cells. In
addition, by expressing high levels of the high aﬃnity IL-2R,
Tregs have an advantage in competing for low levels of IL-2
against eﬀector T-cells in the microenvironment.
A number of contradictory observations regarding the
number and function of nTreg in diabetic individuals and
in mice have been reported. Regulatory T cell numbers
have been reported to be decreased or normal in T1D
[70–79], and functional assays have similarly described low,
slightly decreased, or normal regulatory activity [80–86].
Nevertheless, a consensus regarding a few key points is
developing. (i) There is clear evidence for the existence of
natural regulatory T cells in both pre-T1D and postdiagnosisClinical and Developmental Immunology 7
T1D subjects and mice. (ii) Some of the induced Treg cells
display similar antigen speciﬁcity for β-cell autoantigens
of non-T1D subject’s Tregs [82]. (iii) In vitro and in vivo
expansion of nTreg cells have been successful both in mice
and human, particularly aided by the use of rapamycin
[87, 88].
6.Conclusionand Perspectives
It has now been strongly established that T cell-mediated
dominant immunoregulation is essential for maintain-
ing immunologic self-tolerance and controlling immune
responses to non-self-antigens. Among the various kinds of
Tregs(iTreg, Tr1,and Th3),naturally occurringCD4+CD25+
nTreg play a key role in peripheral self-tolerance. A pro-
teomicapproachmightcontributebettertotheidentiﬁcation
of novel molecules involved in IL-2R signaling pathways
for further therapeutic methods and speciﬁc cell surface
markers for better isolation and characterization purposes.
In vivo, if IL-2 seems to play a critical role in the thymic
development of nTreg, which cells produce IL-2 in the
thymus, at which stage of T-cell development IL-2 exert its
eﬀects, and what is the importance of IL-2 for the nTreg
precursor cells diﬀerentiation are critical questions that need
to be investigated. A possible explanation is that some
thymocytes are conﬁned within special thymic microenvi-
ronments containing high doses of IL-2, which could, in
principle, transform them into anergic Treg cells. Such an
anergic state could be obtained in vitro following Th1 clones
incubation with IL-2 for 24 to 48h. These cells are rendered
unresponsive to subsequent restimulation with antigen [89]
although they remain fully responsive to IL-2 in vitro as
long as IL-2 is provided. However, when restimulated with
appropriate antigen and APC, they do not secrete cytokines,
including IL-2 [90]. With respect to T cell maturation and
central tolerance, not much is known about nTreg cells
thymic maturation/diﬀerentiation. Whereas it is thought
thatnTregcellgenerationdependsonself-antigenexpression
in the thymus [91], a recent report from the Mathis’ group
[92] has shown that nTreg does not necessarily require the
thymic expression of agonistic self-antigen. These questions
and more need to be further investigated. Certainly, the
development of technical tools and animal models will be
invaluable to shed light into naturally occurring Treg biology
and to provide novel immunomodulatory approaches that
target (i) the downregulation of the immune system to
prevent/treatautoimmunediseaseandallograftrejectionand
(ii) the control of immunity to infectious agents such as
parasites and viruses (Figure 2).
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